NHS Queues or Rearmament: Britain's £35bn Test

Two urgent claims on one tax base

Britain's October 2026 Budget exposes an argument that cannot be settled by declaring either hospitals or national security sacred. The government targets defence spending of 3% of gross domestic product by 2030 and 3.5% by 2035. The Office for Budget Responsibility calculates that the increase to 3.5% in 2035 would represent approximately £35 billion a year in 2026–27 prices relative to its base. Meanwhile, NHS England still reports millions of unfinished consultant-led treatment pathways, and the official objective remains to get 92% of patients into treatment within 18 weeks. The possible beneficiaries of military spending include soldiers, contractors, industrial workers and the population whose security a credible deterrent protects. The possible losers include taxpayers and patients if the financing plan leaves health capacity short of demand. Yet the claim that every new defence pound was directly taken from a hospital would be misleading. Departmental budgets have distinct revenue, capital and accounting lines. What connects them is the government's limited fiscal capacity, the cost of borrowing and the number of trained people available to turn cash into results. A responsible comparison asks what the marginal pound achieves in both systems, how much financing is genuinely identified, and whether households see better care and security rather than bigger announcements.

The actual defence trajectory

The defence expenditure (opens in a new tab) trajectory is a sequence of commitments, not an accomplished event. The OBR's October 2026 forecast projects NATO-qualifying defence spending at 2.6% of GDP in 2026–27, 2.7% in 2029–30, 3.0% in 2030–31 and 3.1% in 2031–32. A Ministry of Defence written answer published on November 2 specifies 2.7% in each of 2027–28, 2028–29 and 2029–30 under the current Defence Investment Plan. Those dates matter when politicians describe the 3% promise as if the additional capability already exists. The June funding explainer lists total departmental defence budgets of £68.3 billion in 2026–27, £73.8 billion in 2027–28, £76.5 billion in 2028–29 and £79.1 billion in 2029–30. It also identifies £15 billion of extra Defence Investment Plan resources over four years. These are not all interchangeable: a procurement authorization, an expenditure forecast, actual payment and equipment delivered to a unit are different stages. The Budget also announces innovative financing efforts and up to £5 billion of potential National Wealth Fund and British Business Bank deployment into defence, dual-use and related industries. That is not the same thing as £5 billion of unrestricted cash already spent. The public should demand dated delivery milestones and capability tests rather than count promises as protection.

What the NHS target really measures

The NHS is not an abstract item in a Treasury table. England's consultant-led referral-to-treatment statistics count incomplete pathways for people still awaiting treatment. A single person may have multiple pathways, so the number is not identical to a headcount of distinct patients. The Spending Review 2025 described around 7.4 million waiting pathways at the time and fewer than 60% within 18 weeks, against the target of 92% by the end of the Parliament. Those figures illustrate the scale of the inherited problem; they must not be passed off as a live November 2026 count. NHS England publishes monthly data with revisions, hospital-level variation and specialty differences. The most important measures include the share within 18 weeks, the number of very long waits, the proportion of urgent referrals completed promptly and whether patients obtain effective treatment. The 2025 Spending Review promised NHS England average real-terms day-to-day funding growth of 3.0% a year over 2023–24 through 2028–29, or about £29 billion more in annual resource funding. This is meaningful additional support but not itself proof of restored access. More demand, staff shortages, social-care bottlenecks, building conditions and uneven productivity can absorb the new resources. A government that advertises investment while postponing performance evidence makes it harder to tell which patients actually benefit.

Waiting is an invisible household bill

The cost of a long wait is not limited to the hospital budget. A worker with a painful joint problem may lose hours, decline a promotion or stop working while awaiting a procedure. A person facing a delayed specialist appointment may turn to family members for support; those relatives may reduce their own paid work. A child or older adult may experience preventable deterioration, though the magnitude depends heavily on the condition and its clinical urgency. Some families can purchase private consultations, while others must live with public queues and uncertain treatment dates. Even where the NHS eventually delivers treatment without a charge at the point of use, the interim economic and human cost can be considerable. The correct welfare indicators therefore include pain, mobility, labor-force participation, unpaid care, repeat appointments and variations in waits by region and specialty. They should also examine patient safety and outcomes, because a lower queue achieved by administratively closing pathways would not be a genuine improvement. Hospital productivity gains can create social value when staff and infrastructure allow more people to be treated safely. But a day of waiting avoided in one specialty is not necessarily equivalent to a day avoided in another. The meaningful question is how quickly funding becomes additional, appropriate treatment and restored wellbeing.

Where the defence money comes from

The Defence Investment Plan's June funding explanation is unusually revealing because it names financing components, not just a total. It includes departmental capital-budget reductions, asset sales, support for procurement and international objectives, savings associated with Transport and Energy, and sums still described as requiring funding at Budget 2026. Cuts to capital investment can free fiscal space now, but a canceled or delayed project may have downstream costs in transport efficiency, energy resilience or building maintenance. Asset sales raise money once and cannot sustainably finance permanent annual operating obligations. Better procurement can save genuine money but requires evidence: cost baselines, tender results, supplier performance and reduced lifetime maintenance costs. Borrowing can smooth large national-security investments, but borrowing costs must be included rather than treated as free. This is why fiscal sustainability (opens in a new tab) and defence-industrial production capacity (opens in a new tab) need to be assessed together. A government that funds new weapons by postponing economically productive civilian investment may make future budgets harder to sustain. Conversely, a genuinely effective defence investment can reduce exposure to far more destructive security shocks. Both claims require evidence about what has been delivered. A nominal spending total cannot settle which side of that trade-off has prevailed.

A misleading comparison hides genuine pressure

The Budget's departmental table puts Health and Social Care resource plans at £212.5 billion in 2026–27, but Defence resource departmental limits are not the same accounting concept as the Ministry of Defence's overall expenditure total. Capital spending, transfers, treatment of NATO-qualifying items and multi-year commitments matter. Combining incompatible lines invites a dramatic but false statement about the ratio of a hospital to an aircraft carrier. The OBR assumes NHS day-to-day real resource growth of 2.6% per year after 2028–29, in line with the Spending Review. That is an aggregate forecast assumption, not a guarantee for an individual trust or service. Meanwhile the OBR warns that, once NHS, defence, school and other commitments are taken into account, unprotected day-to-day spending could decline by 2.6% per year in real terms in the last three years of its forecast. It estimates roughly £11 billion of additional resources would be needed in 2031–32 for that category not to fall in real terms relative to 2028–29. These are conditional projections, not an announcement that all unprotected departments will suffer an identical cut. But they reveal a plausible third group of payers: people reliant on local government, courts, transport, care services and other less-protected activities. A serious health-versus-defence debate must not ignore them.

Who decides, who can stop it and who gets paid

The Treasury's Budget sets the proposed fiscal direction, but ministers still need parliamentary authorisation for spending and relevant policy changes. The House of Commons (opens in a new tab) can scrutinize appropriations and call decision makers to account. The Ministry of Defence chooses acquisitions within its rules and must test contractor performance. NHS England and healthcare providers translate resources into appointments, staffing and treatment, subject to safety obligations. The Labour Party (opens in a new tab) has responsibility for the programme it advances, but individual officeholders should be credited or criticised for documented decisions rather than speculative motives. Rachel Reeves (opens in a new tab) is an important figure in the fiscal debate; ministers' claims must be compared with the published Budget, OBR assumptions and supply decisions. Defence suppliers may benefit from contracts, jobs and revenue, but contract award is not profit, and approved finance is not cash paid. Health providers may receive additional allocations yet struggle to recruit clinicians or access operating rooms. Claims about winners should identify the institution, legal authority, payment channel and outcome, rather than assume every stakeholder in a sector gains. Transparent procurement and hospital performance data are the only way to see whether political commitments have reached their intended beneficiaries.

What it moves

The measurable defence indicator is NATO-qualifying expenditure as a share of GDP, but the practical outcome indicators are deployable personnel, available munitions, functional equipment and production lead times. The share is scheduled to rise; improved deterrence is a hoped-for result, not an automatic product of a larger numerator. In healthcare, the key indicators are the percentage of unfinished pathways within 18 weeks, severe waiting-time tails and clinically appropriate completed treatments. Improvement means shorter and more fairly distributed waits with no deterioration in quality. For households, the key indicators are real disposable income, income lost to ill-health, unpaid care burdens and tax changes. For public finances, watch borrowing, debt-interest costs, real departmental funding and gilt yields. The cost-of-living pressure (opens in a new tab) driver and the UK CPI series (opens in a new tab) provide context, but neither proves that a specific defence contract caused an inflation change. For security, the NATO deterrence capacity (opens in a new tab) lens helps distinguish cash allocations from usable strength. All these measures should be reported with dates and comparable definitions. A policy that improves national resilience but slows care has a cost. A policy that accelerates treatment but leaves critical threats unanswered also has one. Officials should quantify both.

The serious case for rearmament

Defence-first advocates have evidence-based concerns. Russia's war against Ukraine has exposed ammunition shortages, fragile supply chains and the need for credible European capabilities. A state that cannot deter attacks on infrastructure, shipping, communications or territory may eventually face vastly larger losses than it spends on readiness. NATO commitments also matter because allies can become less willing to share burdens if national promises repeatedly slip. More investment in drones, air defence, advanced manufacturing and maintenance can create skilled employment and technology that has civilian applications. Deterrence is unusual because the hoped-for success is that weapons never need to be fired in an actual conflict. That makes simple output comparisons with healthcare hard. The argument for military investment should nonetheless specify risk reduction, target availability, realistic timelines and alternative procurement paths. If weapons are delivered years late or without trained crews, taxpayers may pay without purchasing meaningful security. Industrial capacity cannot be conjured simply by announcing an order; production lines and skilled teams need time. A strong security case accepts that real taxpayers finance the programme and demands demonstrable results rather than using patriotism to silence questions about price and implementation.

The serious case for care first

Health-first advocates also have a strong case. People already waiting for operations experience pain and limitations in the present, and improved clinical capacity can return some of them to work and independence. Better access can reduce emergency demand and ease pressure on families. Clinical prevention, community care and diagnostics may be particularly important because expanding hospitals alone is insufficient when discharges are delayed by social-care shortages. A credible healthcare strategy should measure output per real pound spent, staff retention and outcomes, not merely annual departmental growth. Advocates should also acknowledge that a weaker security environment could harm health and economic activity profoundly. Civilian resilience itself depends on hospitals remaining functional during emergencies. The two sectors can complement each other, even though their short-term claims on skilled labour and public money compete. The most productive political question is not which professional group matters more. It is which marginal investments deliver verifiable benefits, which costs could be reduced without lowering quality, and whether the government has exhausted credible ways to reform procurement and care delivery before imposing additional taxes or reducing other public services.

The next test is delivery, not another pledge

The next spending review should publish a funding bridge from the 2.7% plateau to 3% defence by 2030, with named tax, borrowing and spending measures rather than assumed savings. It should show procurement milestones, lifecycle costs, domestic jobs and operational availability, with an explanation of what changes if growth or energy prices disappoint. The NHS should publish measurable progress against the 18-week standard, distribution by specialty and region, and whether improvements reflect safer care rather than changed counting rules. Parliament should demand transparent reporting of the financing costs passed to unprotected departments and how inflation changes their real budgets. The OBR's forecast of pressure on those departments is a warning worth testing, not a verdict that the future cuts are inevitable. For households, the essential evidence is whether taxes rise, wages keep up with prices, and preventable health-related work loss falls. For defence, the evidence is whether commitments become assets that can actually operate when needed. The October 2026 documents define a set of promises; they do not prove the promises have been delivered. A government that can show both shorter queues and stronger deterrence will have earned a powerful argument for its approach. Until then, patients and taxpayers deserve the same clarity about outputs that contractors receive about contract values.

Sources

• HM Treasury, Budget 2026, 28 October 2026 (opens in a new tab)
• Office for Budget Responsibility, October 2026 Economic and Fiscal Outlook (opens in a new tab)
• UK Parliament, Ministry of Defence written answer, 2 November 2026 (opens in a new tab)
• Ministry of Defence, Defence Investment Plan funding explainer, 30 June 2026 (opens in a new tab)
• House of Commons Library, Defence Investment Plan key decisions (opens in a new tab)
• NHS England, Referral to Treatment waiting-time data 2026–27 (opens in a new tab)
• HM Treasury, Spending Review 2025 (opens in a new tab)
• UK Parliament, Defence Investment Plan written statement, 30 June 2026 (opens in a new tab)